Genmab A/S (GMAB) Shares Gain Analyst Support as Deutsche Bank Sees Oncology Upside

TheFly reported connected January 8 that Deutsche Bank raised its terms people for GMAB to DKK 2,400 from DKK 2,000 and reiterated a Buy rating, reflecting analysts’ optimism astir the company’s late-stage oncology pipeline.

Separately, a time earlier, connected January 7, Genmab A/S (NASDAQ:GMAB) partnered with AI probe institution Anthropic to heighten its R&D capabilities utilizing agentic AI powered by Claude models. While keeping quality control, the AI volition automate analyzable information processing and papers creation. The concern is simply a determination toward a much scalable, effective, and digitally enabled R&D process, according to Tahamtan Ahmadi, EVP and Chief Medical Officer.

Genmab A/S (NASDAQ:GMAB) is simply a biotechnology institution specializing successful oncology, processing innovative antibody-based therapies for crab treatment. Its late-stage pipeline includes promising programs similar Rina‑S and Epkinly.

While we admit the imaginable of GMAB arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.